FOLH1 and prostate carcinoma: For example, modification with specific targeting ligands, such as the prostate-specific membrane antigen (PSMA) ligand, has proven to promote the cellular uptake of NPs at the site of prostate cancer, and is already in phase II clinical trials [184].